All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

  TRANSLATE

The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The ALL Hub
Brought to you by Scientific Education Support

The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

EHA 2025 abstracts: What’s hot in ALL?

By Abhilasha Verma

Share:

Jun 9, 2025

Learning objective: After reading this article, learners will be able to cite a new clinical development in acute lymphoblastic leukemia.

To help navigate the exciting content being presented at the European Hematology Association (EHA) 2025 Congress, the ALL Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in ALL. 

EHA 2025: Top abstracts in ALL

Thursday, June 12, 2025 

Abstract # Title Speaker Time CEST 
S271 The B-ALL stromal landscape: Spatial organization and functional specialization of distinct niche subtypes Mauricio Ferrao Blanco 17:15–17:30 

 

Friday, June 13, 2025 

Abstract # Title Speaker Time CEST 
S115 Advancing chemogenomic strategies for functional precision medicine in relapsed/refractory T-ALL and ETP-ALL: Preliminary results of the GIMEMA ALL2720 trial Luca Pagliaro 17:00–17:15 
S116 Achievement of MRD negativity after end of induction with ponatinib and imatinib in the phase III PhALLCON trial: A post hoc analysis Carlo Gambacorti-Passerini 17:15–17:30 
S117 Safety and efficacy of AZD0486 in adolescent and adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia: Early results from the phase I/II SYRUS study Ibrahim Aldoss 17:30–17:45 
S118 Long-term follow-up of an intensive pediatric regimen for adolescents/young adults (AYA) with acute lymphoblastic leukemia (ALL): 10-year survival following CALGB 10403 (ALLIANCE) Wendy Stock 17:45–18:00 
S304 Invasive fungal infections in acute lymphoblastic leukemia: Preliminary results of a multicentric prospective SEIFEM study (ALL-IFI) Chiara Cattaneo  18:00–18:15 
PF348 Optimizing asparaginase hypersensitivity management: Real-world evidence on asparaginase switching practices and guideline adherence Luke Maese 18:30 
PF374 Five-year survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3 Olalekan Oluwole 18:30 
PF377 Real-world effectiveness and safety in adults with minimal residual disease-positive or relapsed/refractory B-cell acute lymphoblastic leukaemia treated with blinatumomab across 13 European countries Sabina Chiaretti 18:30 
PF378 Predicting hematotoxicity risk and outcomes in relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Should hematotox models be CAR specific rather than disease specific Elias Jabbour 18:30 
PF381 Performance of blinatumomab for MRD treatment and bridge to allo-SCT in Ph-negative B-ALL patients treated with pediatric inspired LAL1913 program (subanalysis of the CAMPUS-ALL LAL1913 study). Anna Candoni  18:30 
PF384 Frontline chemotherapy-free combination of olverembatinib with venetoclax and azacitidine in newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study Xiaowen Tang  18:30 
PF386 A prospective study of flumatinib with chemotherapy for newly diagnosed BCR::ABL1-positive acute lymphoblastic leukemia in adults: RJ-ALL2020.2A trial Weiyang Liu 18:30 
PF388 Integrated venetoclax with immunochemotherapy in older or unfit patients with newly diagnosed Philadelphia-negative B-cell acute lymphoblastic leukemia (B-ALL): A phase II multi-center clinical trial Ying Wang 18:30 
PF393 Sinusoidal obstruction syndrome and other outcomes in pediatric patients with acute lymphoblastic leukemia who received inotuzumab ozogamicin before hematopoietic cell transplantation David Marks 18:30 
PF401 Real world analysis of outcomes using a modified DFCI protocol for adults with BCR-ABL negative acute lymphoblastic leukemia - impact of MRD Joseph Brandwein 18:30 
PF403 KTE-X19 in relapsed or refractory adult B-cell acute lymphoblastic leukemia in the Chinese population: A phase II multicenter study Meng Lv 18:30 
PF1089 Outcomes of blinatumomab added to conditioning regimen of allogeneic hematopoietic stem cell transplantation for adult B-cell acute lymphoblastic leukemia patient with low minimal residual disease Jian Yu 18:30 
PF1161 Inotuzumab-based protocols are safe and effective in patients with relapsed/refractory B-acute lymphoblastic leukemia planned for CD19 CAR-T cell therapy Anupa John  18:30 

 

Saturday, June 14, 2025 

Abstract # Title Speaker Time CEST 
PS1341 Efficacy of novel targeted therapies in Down syndrome acute lymphoblastic leukaemia Kunjal Panchal 18:30 
PS1367 Efficacy and safety of regimen with olverembatinib and blinatumomab for the frontline treatment of Ph-positive or Ph-like acute lymphoblastic leukemia Xiuli Xu 18:30 
PS1371 Inotuzumab ozogamicin in pediatric CD22-positive very high risk first relapse B-cell precursor acute lymphoblastic leukemia: Preliminary results of the ITCC-059 study Erica Brivio 18:30 
PS1372 Combination of olverembatinib and VP Regimen as first-line therapy for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A single-arm, multicentre, phase II trial Gaixiang Xu 18:30 
PS1376 Pegaspargase administration in acute lymphoblastic leukemia patients aged 55 years or older treated with the pediatric-inspired program LAL1913. A subanalysis of the CAMPUS ALL study Davide Lazzarotto 18:30 
PS1377 Multicenter real-world study on inotuzumab as a bridge to cellular therapy in relapsed/refractory B-cell acute lymphoblastic leukemia Alicia Aguirre 18:30 
PS1379 Comparative efficacy of the GIMEMA LAL1913 standard chemotherapy protocol versus the standard arm of the E1910 trial IN MRD-negative Ph-negative ALL: A MAIC analysis Alfonso Piciocchi  18:30 
PS1387 Efficacy and safety of the third-generation tyrosine kinase inhibitor olverembatinib in combination with inotuzumab ozogamicin for the treatment of adult Philadelphia chromosome-positive acute lymphoblastic leukemia patients with relapsed disease or persistent minimal residual disease bridging to hematopoietic stem cell transplantation: A phase II study Xiaoyu Zhang  18:30 
PS1394 Outcomes in patients with B-cell precursor acute lymphoblastic leukemia receiving inotuzumab ozogamicin stratified by body mass index Wendy Stock 18:30 
PS1473 Updated results and longer follow-up from the AUGMENT-101 phase II study of revumenib in patients with relapsed or refractory (R/R) KMT2AR acute leukemia Ibrahim Aldoss 18:30 
PS1926 A CAMPUS ALL retrospective multicenter study on the outcome of adult lymphoblastic lymphoma patients treated in the real-life according to the GIMEMA LAL1913 protocol Mario Delia  18:30 
PS2281 Health-related quality of life benefits of frontline ponatinib plus blinatumomab in adult patients with Ph+ acute lymphoblastic leukemia. Preliminary analysis of the GIMEMA ALL2820 trial Laura Cannella  18:30 

 

Sunday, June 15, 2025 

Abstract # Title Speaker Time CEST 
S110 Addition of blinatumomab to consolidation therapy for younger adults (BCR:ABL1-negative B-acute lymphoblastic leukemia (ALL) on the ECOG-ACRIN E1910 phase III trial Shira Dinner  11:00–11:15 
S111 Outcomes in patients with B-cell precursor acute lymphoblastic leukemia receiving inotuzumab ozogamicin stratified by cumulative dose Elias Jabbour 11:15–11:30 
S112 Safety and efficacy of single-agent subcutaneous blinatumomab in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Results from a phase I/II dose expansion study Elias Jabbour 11:30–11:45 
S113 Can CAR T-cell therapy be a definitive treatment for adult R/R B-ALL without transplant? Long-term findings and predictors of sustained remission for obecabtagene autoleucel Jae H. Park  11:45–12:00 
S114 Efficacy and safety outcomes of obecabtagene autoleucel (obe-cel) stratified by age in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) Bijal D. Shah 12:00–12:15 

 

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

B-ALLAZD0486KTE-X19AzacitidineFlumatinibRevumenibEHA 2025Venetoclax BlinatumomabAsparaginasePhiladelphia chromosome-positive / BCR-ABL1ImatinibBrexucabtagene autoleucelPhiladelphia chromosome-negative B-ALLPonatinibPh-like ALLInotuzumab ozogamicinOlverembatinibKMT2A-rearrangementObecabtagene autoleucelB-ALL

Your opinion matters

On average, how many patients with B-cell acute lymphoblastic leukemia do you see in a year?

Related articles

ECOG-ACRIN E1910 subgroup analysis: Impact of age and MRD on blinatumomab outcomes in newly diagnosed Ph− B-ALL

ECOG-ACRIN E1910 subgroup analysis: Impact of age and MRD on blinatumomab outcomes in newly diagnosed Ph− B-ALL

Here, we summarize the subgroup analysis of the ECOG-ACRIN E1910 study evaluating the impact of ag...

Aug 28, 2023

Inotuzumab ozogamicin plus chemotherapy in pediatric B-ALL: ITCC-059 trial

Inotuzumab ozogamicin plus chemotherapy in pediatric B-ALL: ITCC-059 trial

Here, we summarize results from the randomized, phase IB ITCC-059 trial, investigating inotuzumab ozogamicin combined with chemotherapy ...

Feb 9, 2024

Blinatumomab in adult patients with MRD negative B-ALL: Interim results from the ECOG-ACRIN E1910 trial

Blinatumomab in adult patients with MRD negative B-ALL: Interim results from the ECOG-ACRIN E1910 trial

We summarize key findings from the third interim efficacy analysis of the phase III ECOG-ACRIN E1910 trial...

Sep 9, 2024

51st Annual Meeting of the EBMT congress coverage: Transplant and outcomes

51st Annual Meeting of the EBMT congress coverage: Transplant and outcomes

Catch up with our live social media coverage of transplant and outcomes in ALL from the 51st Annual Meeting of the EBMT.

Apr 15, 2025

Newsletter

Subscribe to get the best content delivered to your inbox